Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics

MLA

Nicholas Sicignano, et al. “Risk of Interstitial Lung Disease in Patients Treated for Atrial Fibrillation with Dronedarone versus Other Antiarrhythmics.” Pharmacoepidemiology and Drug Safety, vol. 30, May 2021, pp. 1353–59. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cd725805e80dcd748c35f425cbaff389&authtype=sso&custid=ns315887.

APA

Nicholas Sicignano, Sheila R. Weiss, Earl L. Goehring, Sally Tamayo, Arlene Tave, Chuntao Wu, Juhaeri Juhaeri, Vibha C. A. Desai, Judith K. Jones, & Rhonda L. Bohn. (2021). Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiology and Drug Safety, 30, 1353–1359.

Chicago

Nicholas Sicignano, Sheila R. Weiss, Earl L. Goehring, Sally Tamayo, Arlene Tave, Chuntao Wu, Juhaeri Juhaeri, Vibha C. A. Desai, Judith K. Jones, and Rhonda L. Bohn. 2021. “Risk of Interstitial Lung Disease in Patients Treated for Atrial Fibrillation with Dronedarone versus Other Antiarrhythmics.” Pharmacoepidemiology and Drug Safety 30 (May): 1353–59. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cd725805e80dcd748c35f425cbaff389&authtype=sso&custid=ns315887.